These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The preferred phosphate binder in dialysis patients. Gokal R Perit Dial Int; 1999; 19(5):405-8. PubMed ID: 11379851 [No Abstract] [Full Text] [Related]
8. [Hypercalcaemic crises in patients with chronic renal failure caused by ion-exchange resins, antacidotics and other calcium-containing drugs (author's transl)]. Graben N; Cremer W; Anlauf M; Bock KD Dtsch Med Wochenschr; 1977 Dec; 102(52):1903-7. PubMed ID: 598299 [TBL] [Abstract][Full Text] [Related]
9. [Experience with ion exhcange resins in the calcium phase during the management of hyperkalemia]. Ritz E; Fanz HE; Herzfeld G Dtsch Med Wochenschr; 1969 Jan; 94(2):75-7. PubMed ID: 5782694 [No Abstract] [Full Text] [Related]
10. Treatment of hyperkalemia with a calcium-resin. Berlyne GM; Janabi K; Shaw AB; Hocken AG Lancet; 1966 Jan; 1(7430):169-72. PubMed ID: 4164888 [No Abstract] [Full Text] [Related]
11. Aluminium resin for the treatment of the hyperkalamia of renal failure. Chugh KS; Swales JD; Brown CL; Wrong OM Lancet; 1968 Nov; 2(7575):952-3. PubMed ID: 4176268 [No Abstract] [Full Text] [Related]
12. [Hypercalcemic crises in patients with chronic kidney failure due to calcium-containing ion-exchangers, antacids and other drugs]. Graben N; Cremer W; Anlauf M; Bock KD Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1505-8. PubMed ID: 1030032 [No Abstract] [Full Text] [Related]
13. Hypercalcaemia after oral calcium-carbonate therapy in patients on chronic haemodialysis. Ginsburg DS; Kaplan EL; Katz AI Lancet; 1973 Jun; 1(7815):1271-4. PubMed ID: 4126071 [No Abstract] [Full Text] [Related]
14. [Aluminum hydroxide treatment of hyperphosphatemia in uremia]. Bergquist-Poppen M; Bergström J; Wallin R Lakartidningen; 1972 May; 69(19):2319-20. PubMed ID: 5035811 [No Abstract] [Full Text] [Related]
15. Transient and persistent hypercalcaemia in patients treated by maintenance haemodialysis. Wing AJ; Curtis JR; Eastwood JB; Smith EK; de Wardener HE Br Med J; 1968 Oct; 4(5624):150-2. PubMed ID: 5681049 [TBL] [Abstract][Full Text] [Related]
16. Exchangeable potassium study in patients undergoing chronic haemodialysis. Seedat YK Br Med J; 1969 May; 2(5653):344-5. PubMed ID: 5768459 [TBL] [Abstract][Full Text] [Related]
17. Resin treatment of hyperkalemia. II. Clinical experience with a cation exchange resin (calcium cycle). Frohnert PP; Johnson WJ; Mueller GJ; Tauxe WN; McCall JT J Lab Clin Med; 1968 May; 71(5):840-6. PubMed ID: 5647685 [No Abstract] [Full Text] [Related]
18. Vitamin A toxicity and hypercalcaemia in chronic renal failure. Farrington K; Miller P; Varghese Z; Baillod RA; Moorhead JF Br Med J (Clin Res Ed); 1981 Jun; 282(6281):1999-2002. PubMed ID: 6788164 [TBL] [Abstract][Full Text] [Related]
19. The effect of lowering the serum phosphate on parathyroid hormone secretion and total serum calcium during regular hemodialysis. Hill AV; Thein-Than ; Cook DB; Derr KN; Latner AL Clin Nephrol; 1973; 1(5):284-9. PubMed ID: 4797465 [No Abstract] [Full Text] [Related]
20. Does the choice of phosphate binder affect trace element levels in chronic kidney disease patients treated by regular haemodialysis? Veighey K; Booth J; Davenport A Nephrol Dial Transplant; 2011 Mar; 26(3):1006-10. PubMed ID: 20736253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]